Mammalian Transient Protein Expression Market Size

Mammalian Transient Protein Expression Market size was valued at USD 407.48 million in 2024 and is likely to cross USD 1.09 billion by 2037, expanding at more than 7.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of mammalian transient protein expression is estimated at USD 460.61 million.

The growth of the market can be attributed primarily to the surging prevalence of chronic diseases, such as cardiovascular diseases, cancer, diabetes, kidney failure, and high blood pressure, rising demand for contamination-free and non-toxic methods, and the increasing adoption of antibodies for technological improvement in research activities. Furthermore, the transient protein in mammalian cells is used for the structural, therapeutic, and functional studies, and it is predicted to increase the market’s growth. As per the World Health Organization, cardiovascular diseases claimed the lives of 17.9 million individuals worldwide in 2019, accounting for 32% of all deaths.

Mammalian cell lines are generally used to manufacture diverse immuno- and bio-therapeutic molecules. Key manufacturers are channelizing their efforts to increase the productivity, flexibility, and throughput capabilities as well as redefine control productivity of protein production using mammalian cell lines. The growing prevalence of communicable diseases such as polio, COVID-19, and chicken pox and the increase in the diagnostic population for variant diseases have propelled the overall demand for biological therapeutics, thus providing an opportunistic push to the growth of the global mammalian transient protein expression market. According to the estimations, more than 70% of the population worldwide is administered one dose, and over 60% of the population is administered two doses of the COVID-19 vaccine.